VanEck Associates
DNA icon

VanEck Associates’s Ginkgo Bioworks DNA Stock Holding History

VanEck Associates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-493
Closed -$4K – 1399
2024
Q3 		$4K Sell
493
-145
-23% -$1.45K ﹤0.01% 1360
2024
Q2 		$9K Hold
638
– – ﹤0.01% 1344
2024
Q1 		$30K Buy
638
+45
+8% +$2.33K ﹤0.01% 1304
2023
Q4 		$40K Buy
593
+108
+22% +$6.61K ﹤0.01% 1297
2023
Q3 		$35K Hold
485
– – ﹤0.01% 1305
2023
Q2 		$36K Buy
485
+260
+116% +$15.4K ﹤0.01% 1319
2023
Q1 		$12K Sell
225
-156
-41% -$9.88K ﹤0.01% 1365
2022
Q4 		$26K Buy
381
+62
+19% +$5.7K ﹤0.01% 1345
2022
Q3 		$39K Buy
319
+163
+104% +$19.4K ﹤0.01% 1280
2022
Q2 		$15K Buy
156
+52
+50% +$6.34K ﹤0.01% 1323
2022
Q1 		$17K Hold
104
– – ﹤0.01% 1320
2021
Q4 		$35K Buy
+104
New +$49.4K ﹤0.01% 1310

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

VanEck Associates's DNA Position: Q4 2024 in Review

VanEck Associates sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 493 shares — an estimated $4K sold.

VanEck Associates first reported a position in DNA in Q4 2021 and held it in 12 quarters. The position peaked at $40K in Q4 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • VanEck Associates reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • VanEck Associates sold 493 Ginkgo Bioworks shares in Q4 2024, an estimated $4K.
  • VanEck Associates first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 12 quarters.
  • VanEck Associates's Ginkgo Bioworks position peaked at $40K in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.